Phase 2 Nipocalimab Data Establish Proof of Mechanism in Adults Living with Moderate to Severe Rheumatoid Arthritis, Supporting its Progression into a Combination Study
Drugs.com,
SPRING HOUSE, Pa., Nov. 7, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson